Ocular Therapeutix
OCUL
179 hedge funds and large institutions have $1.14B invested in Ocular Therapeutix in 2024 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 63 increasing their positions, 36 reducing their positions, and 17 closing their positions.
89% more call options, than puts
Call options by funds: $5.19M | Put options by funds: $2.74M
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
75% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 36
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
7% more funds holding
Funds holding: 168 → 179 (+11)
4.63% less ownership
Funds ownership: 89.76% → 85.13% (-4.6%)
6% less capital invested
Capital invested by funds: $1.22B → $1.14B (-$76.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.73M |
| 2 |
BlackRock
New York
|
+$4.8M |
| 3 |
Millennium Management
New York
|
+$4.36M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$2.72M |
| 5 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$24.6M |
| 2 |
PA
Perceptive Advisors
New York
|
-$21.9M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$19.5M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.66M |
| 5 |
SR
Summer Road
West Palm Beach,
Florida
|
-$5.16M |
OCUL Hedge Fund Activity: Q4 2024 in Review
179 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2024, worth a combined $1.14B — down 6.3% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new OCUL positions and 17 closed out — a net gain of 14 holders — while 63 added to existing stakes and 36 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $8.73M. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $24.6M sold.
- 179 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2024, up from 168 in Q3 2024.
- Funds reported $1.14B of Ocular Therapeutix stock for Q4 2024, down 6.3% quarter-over-quarter.
- 31 funds opened new Ocular Therapeutix positions in Q4 2024 and 17 closed out, a net change of +14 holders.
- The largest Ocular Therapeutix buyer in Q4 2024 was Point72 Asset Management, an estimated $8.73M added.
- The largest Ocular Therapeutix seller in Q4 2024 was Assenagon Asset Management, an estimated $24.6M sold.
Based on aggregated 13F filings for Q4 2024.